Finding: At database lock and based on 92 deaths, no difference in overall survival was noted between linsitinib and placebo (median 323 days [95% CI 256–507]  vs  356 days [249–556]; hazard ratio 0·94 [95% CI 0·61–1·44]; p=0·77).
Certainty (1-5): 6